Charles Riv­er keeps adding on to its CD­MO arm, snatch­ing up a vi­ral vec­tor play­er for a tidy $350M

Con­tract re­searcher Charles Riv­er Lab­o­ra­to­ries has been on a roll re­cent­ly to flesh out its man­u­fac­tur­ing arm with a spe­cif­ic fo­cus on its ca­pa­bil­i­ties in gene ther­a­py. Now, the firm is putting its name to a big check for a Mary­land-based vi­ral vec­tor firm it thinks will add to its grow­ing ex­per­tise in the field.

Charles Riv­er will dole out $292.5 mil­lion for gene ther­a­py CD­MO Vi­gene Bio­sciences with the pos­si­bil­i­ty for an ad­di­tion­al $57.5 mil­lion in per­for­mance-based pay­ments, the com­pa­nies said Mon­day. The deal will close at the start of Q3, a Charles Riv­er spokesman said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.